Equities Analysts Set Expectations for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for CervoMed in a report issued on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan forecasts that the company will post earnings of ($0.52) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($2.76) EPS.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The company had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million.

Other research analysts also recently issued reports about the company. Jones Trading raised CervoMed from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Thursday, March 13th. HC Wainwright downgraded CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Brookline Capital Management raised CervoMed from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Chardan Capital raised CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Thursday, March 13th. Finally, Canaccord Genuity Group upped their target price on CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, CervoMed has a consensus rating of “Moderate Buy” and an average target price of $27.50.

CervoMed Stock Up 3.2 %

Shares of CRVO stock opened at $9.34 on Wednesday. The stock has a 50 day simple moving average of $2.73 and a 200-day simple moving average of $7.87. CervoMed has a 1-year low of $1.80 and a 1-year high of $26.38.

Institutional Investors Weigh In On CervoMed

A number of hedge funds have recently modified their holdings of CRVO. Citizens Financial Group Inc. RI grew its holdings in shares of CervoMed by 13.2% in the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock valued at $445,000 after purchasing an additional 3,553 shares during the period. FMR LLC purchased a new stake in shares of CervoMed in the third quarter valued at about $56,000. State Street Corp grew its holdings in shares of CervoMed by 28.1% in the third quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after purchasing an additional 22,903 shares during the period. Barclays PLC grew its holdings in shares of CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after purchasing an additional 5,919 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of CervoMed by 13.9% in the third quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock valued at $1,678,000 after purchasing an additional 14,042 shares during the period. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.